Generics 7

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Treprostinil manufacturers

7 products found

Filters

7 products found

treprostinil

Vials, injection 1 mg/ml, 2.5 mg/ml, 5 mg/ml, 10 mg/ml

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Turkey , Greece
Manufacturer #17347
It was established in the 2000s. Over the years it has become one of the major players in Europe. The commitment to work and obligation towards patients inspires the company to deliver peak performance every day. They want to help – doctors in their work and patients in their recovery. Top-quality, prompt availability, and rapid solutions – especially in critical situations – are particularly important to the company.

Manufacturer usually replies in 12 days

treprostinil

Inhalation solution 0.6 mg / ml

Dossier type
US CTD
Dossier status
Ready to file
Country of origin
United States
GMP approvals
FDA
Manufacturer #17455

Manufacturer usually replies in 7 days

treprostinil

Solution for injection 2.5 mg / ml, 5 mg / ml

Dossier type
US CTD
Dossier status
Ready to file
Country of origin
United States
GMP approvals
FDA
Manufacturer #17455

Manufacturer usually replies in 7 days

Want to see all 7 products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription
Treprostinil is a medication used to treat pulmonary hypertension. Suppliers of treprostinil market it in the form of an inhalable solution, injectable solution as well as immediate-release and extended-release oral tablets. It was first introduced into medical use in 2002 by the developer and earliest manufacturer of the drug United Therapeutics Company under the trade name Remodulin. Currently, it is approved in over 40 countries, including Australia, Taiwan, Japan, and across many EU countries. United Therapeutics Company also markets treprostinil under the trade names Orenitram and Tyvaso. The three drugs together account for around 90 percent of the total treprostinil market share, with remodulin being the most popular medication of the three. A generic version of the drug from Novartis is also available on the market. Treprostinil is a very expensive medication. While 20ml (1mg/ml) of the treprostinil injectable solution is priced at around 2,500 EUR, the equivalent amount of the 2,5mg/ml solution costs 5,400 EUR to 5,600 EUR, and the 5mg/ml solution can cost from 10,000 EUR to 12,000 EUR.

Interested in becoming a subscriber?

Please provide the following information to receive an offer tailored to your business needs

  1. Number of company users for the subscription
  2. The rough number of products you would like to source in the 12 months
  3. Target market(s) for commercialisation